Next Article in Journal
Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2 Breast Cancer Preclinical Models
Previous Article in Journal
Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes
Previous Article in Special Issue
Improving Risk Stratification in pT3 Upper Tract Urothelial Carcinoma: A Focus on Invasion Patterns
 
 
Article

Article Versions Notes

Cancers 2025, 17(7), 1083; https://doi.org/10.3390/cancers17071083
Action Date Notes Link
article xml file uploaded 24 March 2025 10:30 CET Original file -
article xml uploaded. 24 March 2025 10:30 CET Update https://www.mdpi.com/2072-6694/17/7/1083/xml
article pdf uploaded. 24 March 2025 10:30 CET Version of Record https://www.mdpi.com/2072-6694/17/7/1083/pdf
article html file updated 24 March 2025 10:31 CET Original file https://www.mdpi.com/2072-6694/17/7/1083/html
Back to TopTop